Ceapro Inc.

Equities

CZO

CA1499071076

Biotechnology & Medical Research

Delayed Toronto S.E. Other stock markets 01:20:08 2024-05-15 pm EDT			5-day change	1st Jan Change
0.295 ^CAD	+9.26%		+18.00%	+55.26%

Apr. 29	Ceapro Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Apr. 29	Ceapro Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Ceapro Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

April 29, 2024 at 09:01 am EDT

Ceapro Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was CAD 9.63 million compared to CAD 18.84 million a year ago. Net loss was CAD 4.71 million compared to net income of CAD 4.4 million a year ago.

Basic loss per share from continuing operations was CAD 0.06 compared to basic earnings per share from continuing operations of CAD 0.06 a year ago. Diluted loss per share from continuing operations was CAD 0.06 compared to diluted earnings per share from continuing operations of CAD 0.06 a year ago.

Latest news about Ceapro Inc.

Ceapro Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 29	CI
Ceapro Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 29	CI
Ceapro Brief: Parties anticipate completing Transaction in Q2 2024, subject to obtaining all required approvals and satisfying all required conditions	Mar. 28	MT
Ceapro Brief: Says Received Final Court Approval for Merger with Aeterna Zentaris	Mar. 28	MT
Aeterna Zentaris Reports Q4 Net Loss of US$5.6 Million, Provides DETECT Trial Update	Mar. 27	MT
Aeterna Zentaris Brief: Announcing Completion of Enrollment in Ongoing Pivotal DETECT-Trial for Diagnosis of Childhood-Onset Growth Hormone Deficiency	Mar. 27	MT
Aeterna Zentaris Brief: Reporting Q4 Net Loss of US$5.6 million, or $1.16 loss per common share	Mar. 27	MT
Ceapro Brief: Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR Arrangement Agreement to Approve Merger of Equals to Create a Diversified Biopharmaceutical Co	Feb. 26	MT
Aeterna Zentaris and Ceapro Announce Merger of Equals to Create Diversified Biopharmaceutical Co	Dec. 14	MT
Aeterna Zentaris and Ceapro Brief: Cos Announcing Merger of Equals to Create a Diversified Biopharmaceutical Co	Dec. 14	MT
Ceapro Inc. Announces Dosing of First Patients In Phase 1-2a Study of Avenanthramides	Dec. 13	MT
Ceapro Inc. Announces Commencement of Patient Dosing in its Phase 1-2a Study Evaluating its Product, Avenanthramides, for Potential Applications in Managing Conditions Related to Inflammation	Dec. 13	CI
Ceapro Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 29	CI
Aeterna Zentaris Inc. entered into a definitive agreement to acquire Ceapro Inc. for CAD 20 million in a merger of equals transaction.	Nov. 28	CI
Ceapro Inc. Initiates Phase 1-2a Study Assessing Avenanthramides For Potential Applications in Inflammation Based Diseases	Nov. 27	MT
Ceapro Inc. Initiates Phase 1-2A Study Assessing Its Product Avenanthramides for Potential Applications in Inflammation Based Diseases	Nov. 27	CI
Ceapro Inc. Announces the Signing of A Technical Collaboration with NATEX Prozesstechnologie Gmbh to Accelerate the Scale-Up of Its Proprietary PGX Technology Towards Commercial Level	Nov. 07	CI
Ceapro Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-29	CI
Ceapro Extends International Supply and Distribution Agreement with German Provider of Active Ingredients, Symrise	23-08-25	MT
Ceapro Inc. Extends Exclusive International Supply and Distribution Agreement with Symrise	23-08-25	CI
Ceapro Announces Next Phase of Research Collaboration with the Angiogenesis Foundation	23-07-18	MT
Ceapro Inc. Announces Next Phase of Research Collaboration with the Angiogenesis Foundation	23-07-18	CI
Ceapro Inc. Announces Resignation of Glenn Rourke as A Director	23-06-07	CI
Ceapro Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-25	CI
Ceapro Inc. Presents Encouraging Results from Research Collaboration Study with McMaster University Evaluating PGX-Processed Yeast Beta Glucan for Interstitial Lung Diseases	23-05-23	CI

Chart Ceapro Inc.

Duration

Period

More charts

Company Profile

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.

Sector

Biotechnology & Medical Research

Calendar

2024-05-22 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CEAPRO INC.	+55.26%	15.49M
MODERNA, INC.	+28.66%	49.18B
IQVIA HOLDINGS INC.	+0.96%	42.11B
LONZA GROUP AG	+50.47%	40.37B
CELLTRION, INC.	-5.26%	28.85B
ICON PUBLIC LIMITED COMPANY	+13.38%	26.09B
ALNYLAM PHARMACEUTICALS, INC.	-22.60%	18.71B
BIO-TECHNE CORPORATION	+8.07%	13.26B
MEDPACE HOLDINGS, INC.	+32.17%	12.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.37%	11.99B

Other Biotechnology & Medical Research